Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18133469 | 1.00 | TP53 (0.41) | TP53HSD11B1ALDH1A1RECQLKDM4E | |
| SCHEMBL20009061 | 1.00 | TP53 (0.41) | TP53HSD11B1ALDH1A1RECQLKDM4E | |
| SCHEMBL19369363 | 0.82 | TP53 (0.37) | TP53HSD11B1ALDH1A1RECQLKDM4E | |
| SCHEMBL19369063 | 0.82 | TP53 (0.37) | TP53HSD11B1ALDH1A1RECQLKDM4E | |
| SCHEMBL20248308 | 0.82 | TP53 (0.37) | TP53HSD11B1ALDH1A1RECQLKDM4E | |
| SCHEMBL19369062 | 0.82 | TP53 (0.37) | TP53HSD11B1ALDH1A1RECQLKDM4E | |
| SCHEMBL20008977 | 0.81 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL20008953 | 0.81 | KDM4E (0.35) | HSD11B1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL25275910 | 0.81 | TP53 (0.36) | TP53HSD11B1ALDH1A1RECQLKDM4E | |
| SCHEMBL25281278 | 0.77 | TSHR (0.35) | TP53HSD11B1ALDH1A1RECQLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-26 | — | — | US | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037323-B2 | Uracil derivatives as Mer-AXL inhibitors | MERTK, DAPK1, AXL | TP53 12/4885HSD11B1 4296/4885ALDH1A1 1072/4885 |
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | TP53 475/4885HSD11B1 2021/4885ALDH1A1 3032/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | TP53 475/4885HSD11B1 2021/4885ALDH1A1 3032/4885 |
| US-20230339891-A1 | URACIL DERIVATIVES AS MER-AXL INHIBITORS | MERTK, DAPK1, AXL | TP53 12/4885HSD11B1 4296/4885ALDH1A1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.